Get the Stockscreener App
38.01
0.26%
-0.10
Rhythm Pharmaceuticals Inc. stock is currently priced at $38.01, with a 24-hour trading volume of 615.93K.
It has seen a -0.26% decreased in the last 24 hours and a -2.84% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $38.21 pivot point. If it approaches the $37.52 support level, significant changes may occur.
Rhythm Pharmaceuticals Inc. Stock (RYTM) Financials Data
Rhythm Pharmaceuticals Inc. (RYTM) Revenue 2024
RYTM reported a revenue (TTM) of $77.43 million for the quarter ending December 31, 2023, a +227.56% rise year-over-year.
Rhythm Pharmaceuticals Inc. (RYTM) Net Income 2024
RYTM net income (TTM) was -$184.68 million for the quarter ending December 31, 2023, a -1.97% decrease year-over-year.
Rhythm Pharmaceuticals Inc. (RYTM) Cash Flow 2024
RYTM recorded a free cash flow (TTM) of -$136.20 million for the quarter ending December 31, 2023, a +23.36% increase year-over-year.
Rhythm Pharmaceuticals Inc. (RYTM) Earnings per Share 2024
RYTM earnings per share (TTM) was -$3.20 for the quarter ending December 31, 2023, a +8.05% growth year-over-year.
Rhythm Pharmaceuticals Inc. Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shulman Joseph | Chief Technical Officer |
Mar 21 '24 |
Sale |
40.34 |
18,235 |
735,600 |
30 |
| Lee Jennifer Kayden | EVP, Head of North America |
Mar 20 '24 |
Sale |
38.77 |
18,235 |
707,005 |
6,852 |
| Meeker David P | President and CEO |
Mar 19 '24 |
Sale |
39.22 |
45,494 |
1,784,275 |
174,605 |
| Mazabraud Yann | EVP, Head of International |
Mar 19 '24 |
Sale |
39.22 |
16,000 |
627,520 |
24,495 |
| Smith Hunter C | Chief Financial Officer |
Mar 19 '24 |
Sale |
39.22 |
15,515 |
608,498 |
97,939 |
| Shulman Joseph | Chief Technical Officer |
Mar 19 '24 |
Sale |
39.22 |
15,515 |
608,498 |
18,265 |
| Lee Jennifer Kayden | EVP, Head of North America |
Mar 19 '24 |
Sale |
39.22 |
15,515 |
608,498 |
25,087 |
| Cramer Pamela J. | Chief Human Resources Officer |
Mar 19 '24 |
Sale |
39.22 |
15,515 |
608,498 |
30,005 |
| Shulman Joseph | Chief Technical Officer |
Feb 14 '24 |
Sale |
50.01 |
1,089 |
54,461 |
30 |
| Shulman Joseph | Chief Technical Officer |
Feb 13 '24 |
Sale |
50.00 |
1,865 |
93,250 |
1,119 |
Rhythm Pharmaceuticals Inc. Stock (RYTM) Latest News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GlobeNewswire Inc.
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Benzinga
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Zacks Investment Research
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
GlobeNewswire Inc.
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
GlobeNewswire Inc.
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GlobeNewswire Inc.
About Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.
COMPANY PROFILE
NameRhythm Pharmaceuticals Inc.
SectorHealthcare (1201)
IndustryBiotechnology (691)
Webrhythmtx.com
Phone857-264-4280
Employee43
Twitter
@rhythmpharma
SEC filings
Latest SEC Filings
Next earning date2024-04-30
Address500 Boylston Street, 11th Floor, Boston, MA, United States (2116)
1.85%
1.31%
Cap:
|
Volume (24h):